First Semester M.Pharm Degree Regular/Supplementary Examinations March 2020 M.Pharm (Pharmaceutics)

Paper IV – Regulatory Affairs (MPH 104T)

(Common for 2017 and 2019 Scheme)

Time: 3 Hours

QP CODE: 114327

- Answer all questions to the point neatly and legibly
 Do not leave any blank pages between answers
 Indicate the question number correctly for the answer in the margin space
- Answer all parts of a single question together Leave sufficient space between answers
- Draw table/diagrams/flow charts wherever necessary

Essays

- 1. Explain the in vitro performance requirements for generic applications.
- 2. Describe the guidelines for non-clinical drug development for global submission
- 3. Explain the CMC (chemistry, manufacturing and control) for market authorization

Short Notes

- 4. The post marketing surveillance.
- 5. The regulatory requirement for product approval of API.
- 6. The importance of eCTD in regulatory application submission.
- 7. The regulatory requirements of TGA.
- 8. The importance of HIPAA in clinical studies
- 9. The clinical protocol for submitting NDA.
- 10. Institutional review board and procedures.
- 11. Outsourcing BA and BE to CRO.
- 12.ICH guidelines.

Reg. No:....

(9x5=45)

(3x10=30)

Total Marks: 75